Hysteroscopy Does Not Worsen Prognosis in Stage II Endometrial Carcinoma
Hysteroscopy is oncologically safe for patients with stage II endometrial carcinoma and does not adversely affect prognosis, recurrence rates, or survival outcomes. The most recent and highest-quality evidence demonstrates no significant impact on disease-free survival, overall survival, or positive peritoneal cytology rates.
Evidence Supporting Safety
The 2025 systematic review and meta-analysis 1 provides the strongest contemporary evidence, showing:
- No significant difference in positive peritoneal cytology between hysteroscopy and control groups (p = 0.13 in retrospective/prospective studies; p = 0.61 in RCTs)
- No impact on disease-free survival (RR = 0.88; 95% CI, 0.75-1.05; p = 0.16)
- No effect on overall survival (RR = 0.99; 95% CI, 0.83-1.18; p = 0.90)
This is corroborated by the 2022 multicenter retrospective study of 1,731 patients 2, which found no association between hysteroscopy and:
- Relapse rate (HR 1.24,95% CI 0.92-1.66; p = 0.16)
- Disease-free survival (HR 1.23,95% CI 0.92-1.66; p = 0.15)
- Overall survival (HR 0.95% CI 0.70-1.29; p = 0.76)
Guideline Recommendations for Stage II Disease
Current ESMO guidelines 3 recommend hysteroscopy as part of the diagnostic pathway for endometrial cancer, noting it is "highly accurate and clinically useful in diagnosing endometrial cancer" 3. The guidelines emphasize that hysteroscopy with biopsy should be used as the final diagnostic step when needed.
For stage II disease specifically, the treatment approach focuses on:
- Stage IIA (endocervical glandular involvement only): Treated as stage I disease 4
- Stage IIB (cervical stromal invasion): Extended radical hysterectomy, bilateral salpingo-oophorectomy, and lymph node dissection 4, 3, 4
The 2025 ESGO-ESTRO-ESP guidelines 5 clarify that for stage II disease with cervical involvement, more extensive procedures should only be performed if required to achieve free surgical margins, and simple hysterectomy with postoperative radiotherapy is often sufficient.
Key Clinical Considerations
Technique matters for safety:
- Use appropriate distension medium and controlled inflation pressure 6
- Avoid prolonged examination times
- Maintain standardized protocols 1
The historical concern about tumor dissemination is unfounded. Multiple large studies across different populations (Chinese 7, European 2, and international cohorts 1) consistently demonstrate that hysteroscopy does not increase:
- Positive peritoneal cytology rates (4.76% vs 3.23%, p = 0.137) 7
- Risk of upstaging
- Recurrence patterns
For type II endometrial cancers (serous, clear cell), which are more aggressive histologies, the 2022 study 8 specifically examined 429 patients with apparent early-stage type II disease and found no difference in 5-year disease-free survival (72.17% vs 76.16%, p = 0.281) or overall survival (67.23% vs 70.71%, p = 0.573) between hysteroscopy and D&C groups.
Common Pitfalls to Avoid
- Do not avoid hysteroscopy based on outdated concerns about tumor dissemination—this fear is not supported by current evidence
- Do not confuse diagnostic hysteroscopy with operative hysteroscopy—the safety data applies to diagnostic procedures with directed biopsy
- Do not perform more radical surgery than necessary for stage II disease—the 2019 CA Cancer Journal 9 and 2025 guidelines 5 emphasize that simple hysterectomy with adjuvant radiotherapy is often adequate
Bottom Line for Stage II Disease
Proceed with hysteroscopy for diagnosis without concern for worsening prognosis. The diagnostic accuracy benefits (particularly for assessing cervical involvement 7) outweigh any theoretical risks, which have been definitively disproven by multiple high-quality studies. Focus treatment decisions on established prognostic factors (grade, depth of invasion, lymphovascular space invasion, molecular classification) rather than the diagnostic method used 5, 10.